Search

Policy & advocacy

Our mandateEHA’s policy and advocacy work is guided by the European Affairs Committee, which sets the priorities, formulates positions and actively contributes to engagement with policy makers and stakeholders.

Read more

Commonalities and Differences in Myeloid Malignancies: Insights from the EHA-SWG Scientific Meeting on MDS, MPN, and AML

November 2-4 - Budapest, Hungary

Meeting Chairs:

Konstanze Döhner, University Hospital Ulm, Germany
Claire Harrison, Guy's and St.

Read more

Chairs and Members

Chair (re-appointment, 2023–2026)Josef Vormoor—Professor of Hematological Malignancies in Children, University Medical Center Utrecht (The Netherlands)

Co-chair (re-appointment, 2023–2026)Maria Ester Bernardo—Clinical Coordinator, Clinical Research Unit, San Raffaele Telethon Institute for Gene Therapy (Italy)

SWG Steering Committee members (2024–2027 term)
SWG Secretary—Francesco Saglio, AOU Città…

Read more

EHA remembers Tessa Holyoake

The Hague, September 2017

We received the sad news of Professor Tessa Holyoake’s passing. Tessa Holyoake was a Professor of Experimental Hematology and the Head of the Paul O'Gorman Leukemia Research Centre.

Read more

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).

Read more

ASCERTAIN: EHA joins consortium aiming for better pricing and reimbursement models

November 28, 2022
EHA is a partner in the ASCERTAIN consortium which will develop models for the pricing, cost-benefit assessment, and reimbursement of innovative health technologies in Europe.

Read more

EHA-SWG Scientific Meetings

On this page, you can browse and/or download the interactive EHA-SWG Scientific Meetings Sponsor Program, which will be released early December.

Read more